Recent news on Verteporfin

Combination of bevacizumab, PDT shows promise  -  May 22, 2007
OSN SuperSite (subscription),PARIS — A combination of bevacizumab intravitreal injection with verteporfin photodynamic therapy clears choroidal neovascularization from the eyes of the

Study Fails to Demonstrate Differences between Intravitreal ...  -  May 14, 2007
DG NewsWe would use verteporfin PDT to close down the neovascularisation from AMD, but then use an antiangiogenic therapy to prevent angiogenesis after that

Ranibizumab, PDT combination successfully treats neovascular AMD  -  May 11, 2007
OSN SuperSite (subscription),Combined treatment with intravitreal ranibizumab and verteporfin photodynamic therapy is more effective against neovascular age-related macular degeneration

Study Confirms Improvements in Visual Function and Quality of Life ...  -  May 14, 2007
DG News...after 24 months of treatment with ranibizumab (Lucentis) as compared with those who are treated with verteporfin-based photodynamic therapy alone,

Triple Therapy Beats Double Therapy for Treating CNV After Age ...  -  May 8, 2007
DG NewsIn the study, 17 patients with classic subfoveal CNV who were treated with photodynamic therapy (PDT) with verteporfin, combined with intravitreal

CHMP confirms recommends deleting 'occult' indication of Visudyne ...  -  Apr 27, 2007
Forbes,...report from its April meeting that it has recommended that the 'occult' indication for the age-related blindness drug Visudyne (verteporfin) be deleted.

European regulators considering dropping Visudyne's approved ...  -  Apr 25, 2007
OSN SuperSite (subscription),Such a decision is not expected to affect Visudyne's (verteporfin) other indications for treating predominately classic or pathologic myopia, according to

Less vision preserved from PDT, anti-VEGF treatment combination  -  May 17, 2007
OSN SuperSite (subscription),Olivier Lebreton, MD, and colleagues in Nantes, France, conducted a study evaluating the effects of secondary treatment with Visudyne (verteporfin,

Retinal Pigment Epithelial Tears Associated With Bevacizumab ...  -  May 14, 2007
DG News...with pegaptanib (Macugen), ranibizumab (Lucentis), and photodynamic therapy (verteporfin PDT), Dr. Rosenblatt explained in his poster presentation.

Meeting Highlights From The Committee For Medicinal Products For ...  -  Apr 27, 2007
Medical News Today (press release),The CHMP recommended that the indication for Visudyne (verteporfin), from Novartis Europharm Ltd, in the treatment of occult subfoveal choroidal

European regulators considering dropping Visudyne's approved ...  -  26 Apr 2007
OSN SuperSite (subscription),Such a decision is not expected to affect Visudyne's (verteporfin) other indications for treating predominately classic or pathologic myopia, according to

Visudyne sales drop more than 40% during first quarter  -  Apr 23, 2007
OSN SuperSite (subscription),Visudyne (verteporfin) sales in the United States declined 13.7% during the quarter and totaled about $8.4 million. However, US sales appeared to stabilize

QLT Announces First Quarter 2007 Visudyne Sales  -  Apr 23, 2007
PharmaLive.com (press release),VANCOUVER, April 23, 2007 /PRNewswire-FirstCall/ - QLT Inc. today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin)

QLT announces first quarter 2007 Visudyne(R) sales  -  Apr 22, 2007
American Digital Networks (press release),...reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of US$61.2 million for the quarter ended March 31, 2007 .

QLT announces first quarter 2007 Visudyne(R) sales  -  Apr 22, 2007
Canada NewsWire (press release),VANCOUVER, April 23 /CNW/ - QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin)

Repeated bevacizumab injections similarly effective to initial ...  -  Apr 11, 2007
OSN SuperSite (subscription),In 20% of cases, surgeons also performed Visudyne (verteporfin, Novartis/QLT) photodynamic therapy at the time of the initial intravitreal bevacizumab

Sirion Series B Raises $45M For Phase III Ophthalmic Bid  -  Apr 9, 2007
BioWorld Online,..."Right now, there really isn't anything out there treating dry AMD - it's like before Visudyne [verteporfin, QLT Inc.] there wasn't anybody treating wet AMD

PDT more effective for myopic CNV in patients 55 years and younger ...  -  Mar 8, 2007
OSN SuperSite (subscription),Alfredo Pece, MD, of Melegnano Hospital in Milan, Italy, and colleagues evaluated outcomes of 49 eyes of 48 patients treated with verteporfin PDT for

Two-year ANCHOR results favor ranibizumab over PDT in AMD  -  Mar 2, 2007
OSN SuperSite (subscription),The study included 423 patients randomly assigned to receive 0.3 mg or 0.5 mg of ranibizumab along with sham verteporfin PDT or sham injections plus active

Tolmar in sale-leaseback deal to snap up QLT USA  -  Feb 6, 2007
In-PharmaTechnologist.com,The company's top product, Visudyne (verteporfin for injection), for the treatment of certain forms of wet age-related macular degeneration (AMD),

QLT reports Visudyne eye treatment sales for Q4 declined by 28.7%  -  18 Jan 2007
Canada.com,Visudyne, or verteporfin, is used to treat age-related macular degeneration, a major cause of blindess. Visudyne sales in the US alone for the fourth

Advances in the Treatment of Age-Related Macular Degeneration  -  Dec 18, 2006
Medscape (subscription)These articles clearly showed that ranibizumab has much greater efficacy than previous treatments (ie, photodynamic therapy [PDT] with verteporfin,

Unlicensed eye disease drug used on Kiwis  -  Dec 3, 2006
Stuff.co.nz,The Press has seen a Pharmac analysis, requested by district health boards, which compares Avastin with another treatment, verteporfin photodynamic therapy.

QLT announces jury decision on trial of Massachusetts Eye and Ear ...  Nov 6, 2006
The '349 Patent claims certain inventions relating to the use of verteporfin as the photoactive agent in the treatment of certain eye diseases including Age ... -Yahoo! News (press release) QLT cuts annual forecast after Q3 sales of Visudyne fall 39.3% to ...  Oct 19, 2006
26. QLT reported that partner Novartis AG (NYSE:NVS) had announced its global sales of Visudyne, or verteporfin, of US$75.1 million. ... -CBC News, QLT cuts annual forecast after Q3 sales of Visudyne fall 39.3% to ...  Oct 19, 2006
26. QLT reported that partner Novartis AG had announced its global sales of Visudyne, or verteporfin, which is used against age-related macular degeneration. ... -CBC News, QLT's Global Sales Of Visudyne Down 39.3% In Q3; Lowers FY06 ...  Oct 19, 2006
...charts | news | PowerRating) said that NOVARTIS AG ADS (NVS | charts | news | PowerRating) announced global sales of QLT's Visudyne or verteporfin product of US ... -Trading Markets, QLT announces Visudyne(R) sales for third quarter of 2006 and ...  Oct 18, 2006
...(NASDAQ:QLTI - News; TSX:QLT - News) today reported that Novartis AG announced global sales of QLT's Visudyne® (verteporfin) product of US$75.1 million for ... -Yahoo! News (press release) QLT announces Visudyne(R) sales for third quarter of 2006 and ...  Oct 19, 2006
VANCOUVER, Oct. 19 /CNW/ - QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of ... -CNW Telbec (Communiqués de presse), QLT Announces Visudyne Sales for Third Quarter of 2006 and Updates ...  Oct 19, 2006
...today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of US$75.1 million for the quarter ended September 30, 2006. ... -PharmaLive.com (press release), New England Journal of Medicine Publishes Data From Lucentis ...  Oct 9, 2006
...is a Phase III randomized, multi-center, double-masked, active-treatment controlled study comparing two different doses of LUCENTIS to verteporfin (Visudyne(R ... -Drug Newswire (press release), QLT announces Visudyne(R) sales for third quarter of 2006 and ...  Oct 18, 2006
...(NASDAQ:QLTI; TSX:QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of US$75.1 million for the quarter ... -MSN Money QLT provides update on Massachusetts Eye and Ear Infirmary ...  Oct 9, 2006
...the District of Massachusetts seeking to establish exclusive rights for MEEI as the owner of certain inventions related to the use of verteporfin (the active ... -Drug Newswire (press release), International Approvals: Azilect and Lucentis  Sep 11, 2006
...was linked to an average 11.3-letter gain from baseline at 1 year compared with a loss of 9.5 letters in those given verteporfin photodynamic therapy (Visudyne ... -Medscape (subscription)

Unlicensed eye disease drug used on Kiwis  -  Dec 3, 2006
Stuff.co.nz,The Press has seen a Pharmac analysis, requested by district health boards, which compares Avastin with another treatment, verteporfin photodynamic therapy.

Yellow Pigment in Veggies Protects Against Eye Disease  Aug 15, 2006
Photodynamic therapy. A drug called verteporfin is injected into your arm. It travels throughout the body, including the new blood vessels in your eye. ... -Food Consumer

Genentech/Novartis Ophthalmics' Lucentis will Dominate the Market ...  Aug 9, 2006
...wet AMD market either as a monotherapy or in combination with the current standard of care, QLT/Novartis Ophthalmics' Visudyne (verteporfin/photodynamic therapy ... -PR Newswire

Digital Healthcare Clinical Trials iP® Software (VPDT) Used in ...  Jun 29, 2006
Healthcare is pleased to announce the use of its innovative Clinical Trials iP® software in a pioneering study involving Verteporfin Photodynamic Therapy (VPDT ... -Emediawire

Software offers new hope for AMD sufferers  Jun 23, 2006
Results will be used to measure the effectiveness of the laser-activated drug Verteporfin (known as Verteporfin Photodynamic Therapy) to treat wet AMD. ... -Optician Journal

QLT announces Visudyne(R) sales for second quarter of 2006  Jul 16, 2006
...(NASDAQ:QLTI - News; TSX:QLT - News) today reported that Novartis AG announced global sales of QLT's Visudyne® (verteporfin) product of US$95.3 million for ... -Yahoo! News

QLT announces Visudyne(R) sales for second quarter of 2006  Jul 17, 2006
VANCOUVER, July 17 /CNW/ - QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of ... -CNW Telbec (Communiqués de presse)

QLT announces Visudyne Sales for Second Quarter of 2006  Jul 17, 2006
...today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of US$95.3 million for the quarter ended June 30, 2006. ... -PharmaLive.com

QLT announces Visudyne(R) sales for second quarter of 2006  Jul 16, 2006
...(NASDAQ:QLTI; TSX:QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of US$95.3 million for the quarter ... -PR Newswire

Software used in study of treatment for blindness  Jul 4, 2006
The results from this study will be used to measure the effectiveness of a specialist drug and laser therapy (verteporfin photodynamic therapy) as a treatment ... -Laboratory Talk

· Some words from our sponsors  Jun 21, 2006
The results from this study will be used to measure the effectiveness of a specialist drug and laser therapy (Verteporfin Photodynamic Therapy) as a treatment ... -Silicon Fen Business Report



Triple Regimen Safe and Effective for Choroidal Neovascularization ...  May 2, 2006
Patients received 10 mg of intravitreal triamcinolone initially, followed by standard verteporfin PDT, and finally, intravitreal injections of Macugen 0.3 mg ... - DG News

QLT announces Visudyne(R) sales for first quarter of 2006  Apr 23, 2006
...(NASDAQ: QLTI; TSX: QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of approximately US$106.8 million ... - MSN Money

QLT Announces Visudyne Sales for First Quarter of 2006  Apr 24, 2006
...today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of approximately US$106.8 million for the quarter ended March ... - PharmaLive.com

QLT announces Visudyne(R) sales for first quarter of 2006  Apr 23, 2006
...(NASDAQ: QLTI - News; TSX: QLT - News) today reported that Novartis AG announced global sales of QLT's Visudyne® (verteporfin) product of approximately US ... - Yahoo! News





Genentech Granted Six-Month Priority Review for Lucentis for the ...  Feb 28, 2006
In addition, Lucentis is the first investigational therapy to have demonstrated a clinical benefit compared to verteporfin (Visudyne(R)) photodynamic therapy ... - International News Service,

Genaera Announces Interim EVIZON(TM) Phase II (MSI-1256F-209) Data  Mar 1, 2006
...percent. This effect was significantly more pronounced in subjects who did not receive photodynamic therapy with verteporfin (PDT). ... - PR Newswire,

Bausch & Lomb Teams with Novartis Ophthalmics To Co-Promote Bausch ...  Feb 9, 2006
Retisert is a trademark of Bausch & Lomb Incorporated. Visudyne (verteporfin for injection) is a registered trademark ofNovartis. - Finanzen.net,

Pfizer's Macugen cleared for marketing in EU  Feb 3, 2006
At present, the market for AMD therapies is valued at around $600 million, with Novartis/QLT's photodynamic therapy Visudyne (verteporfin) dominating the ... - Pharma Times (subscription),

Bausch & Lomb Teams with Novartis Ophthalmics To Co-Promote Bausch ...  09 Feb 2006
..."Novartis has an extensive physician-specialist network in place for its Visudyne(R) (verteporfin for injection) therapy for the predominantly classic wet form ... - Genetic Engineering News

Bausch & Lomb Teams with Novartis Ophthalmics To Co-Promote Bausch ...  09 Feb 2006
Retisert is a trademark of Bausch & Lomb Incorporated. Visudyne (verteporfin for injection) is a registered trademark ofNovartis. - Finanzen.net

Pfizer's Macugen cleared for marketing in EU  Feb 3, 2006
At present, the market for AMD therapies is valued at around $600 million, with Novartis/QLT's photodynamic therapy Visudyne (verteporfin) dominating the ... - Pharma Times (subscription)

Preliminary Phase III Data from Head-To-Head Study of Lucentis ...  Jan 14, 2006
Data from the ANCHOR study comparing Lucentis to verteporfin (Visudyne®) photodynamic therapy (PDT) showed a difference in mean change in visual acuity of 18 ... - Yahoo! News

QLT announces Visudyne(R) sales for fourth quarter and fiscal year ...  Jan 19, 2006
...(NASDAQ:QLTI; TSX:QLT) today reported that its alliance partner, Novartis, announced global Visudyne(R) (verteporfin) sales of approximately US$108 million for ... - Biotech Intelligence

QLT announces Visudyne(R) sales for fourth quarter and fiscal year ...  Jan 19, 2006
19 /CNW/ - QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that its alliance partner, Novartis, announced global Visudyne(R) (verteporfin) sales of ... - CNW Telbec (Communiqués de presse)

QLT Announces Visudyne Sales for Fourth Quarter and Fiscal Year ...  Jan 19, 2006
...today reported that its alliance partner, Novartis, announced global Visudyne(R) (verteporfin) sales of approximately US$108 million for the quarter and US$484 ... - PharmaLive.com

QLT announces Visudyne(R) sales for fourth quarter and fiscal year ...  Jan 18, 2006
...(NASDAQ:QLTI - News; TSX:QLT - News) today reported that its alliance partner, Novartis, announced global Visudyne® (verteporfin) sales of approximately US ... - Yahoo! News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional